Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Illustration showing large scissors cutting employees in half

Layoffs

Kezar Loses 70% of Staff After FDA Cancels Meeting on Autoimmune Asset

Kezar Life Sciences suffered multiple clinical holds and four patient deaths in a trial testing zetomipzomib for lupus—a program that has since been canned. The company is still pursuing development in autoimmune hepatitis, but recent FDA communications could delay its timeline.

November 10, 2025

2 min read

Dan Samorodnitsky

FDA

FDA Removes Black Box Warning From HRT Products, Reversing Landmark Decision

After a leading study caused the FDA to slap its most stringent warning on hormone replacement therapies for menopause more than two decades ago, the regulator is changing course in what FDA Commissioner Marty Makary called a “historic day for women in the United States.”

November 10, 2025

2 min read

Heather McKenzie

Obesity

Despite Obesity Drug Pricing Deal, GLP-1 Compounders Continue To Operate in the Shadows

The White House may have struck a deal with Eli Lilly and Novo Nordisk last week to lower the costs of their weight loss drugs for patients, but knockoff versions of Zepbound and Wegovy still permeate the obesity market.

November 10, 2025

3 min read

Dan Samorodnitsky

Digital illustration of human eye color modification and futuristic vision. Made with vector vibrant color gradient geometry form. Isolated on colorful textured background.

Gene therapy

Lilly Doubles Down on Eye Diseases, Adding to BD Spree

MeiraGTx Holdings is licensing a genetic eye disease medicine to Eli Lilly in a deal worth up to $475 million.

November 10, 2025

1 min read

Annalee Armstrong

Modern collage with human heart and hands stock illustration

Cardiovascular disease

Ionis’ Tryngolza ‘Game-Changing’ in Lowering Triglycerides, Cementing Case for FDA Filing

Ionis is planning a supplemental submission by the end of the year to expand Tryngolza into severe hypertriglyceridemia. If granted, William Blair expects the antisense drug to be “transformational” for this indication.

November 10, 2025

2 min read

Tristan Manalac

Amgen sign at its headquarters in Thousand Oaks, California, USA.

Cardiovascular disease

Amgen’s Repatha Cuts Risk of First Heart Attack by 36% in Phase III Trial

The cholesterol-lowering drug is part of a suite of medicines that also includes MariTide and that Amgen Chief Medical Officer Paul Burton hopes will make the company the “undisputed leader in the management of cardiometabolic risk for patients” by 2030.

November 10, 2025

4 min read

Heather McKenzie

Indianapolis, U.S. - April 16, 2016: Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals VII

Metabolic disorders

Lilly Makes $1.2B RNAi Pact With SangeneBio, Targets Metabolic Diseases

Eli Lilly has been on a dealmaking spree this year, with a few deals worth $1 billion or more. Aside from SangeneBio, these include SiteOne, Verve and Scorpion.

November 10, 2025

2 min read

Tristan Manalac

ransparent plastic tube being blocked by orange balls on blue background. Illustration of the concept of digestive disorders and difficulties on career paths

Cardiovascular disease

Merck Builds Case for Cholesterol-Lowering Pill With Injectable-Like Efficacy

Multiple analyst firms were impressed by the Phase III data, which showed that Merck’s oral PCSK9 inhibitor can lower low-density lipoprotein cholesterol by more than 55% after 24 weeks.

November 10, 2025

2 min read

Tristan Manalac